BIOXYTRAN, INC (BIXT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 200K 400K 600K Q1 '11: 21.3K Q2 '11: 46.9K Q3 '11: 58.3K Q4 '11: 76.3K Q1 '12: 201.8K Q2 '12: 288.5K Q1 '13: 289.5K Q2 '13: 262.8K Q1 '14: 511.4K Q4 '14: 275.6K Q1 '15: 129.8K Q2 '15: 151.3K Q3 '15: 220.6K Q4 '15: 255.8K Q1 '16: 224.9K Q2 '16: 221.1K Q3 '16: 211.4K Q4 '16: 246.5K Q1 '17: 222.4K Q2 '17: 206.2K Q2 '11 Q1 '12 Q2 '13 Q1 '15 Q4 '15 Q3 '16 Q2 '17

Gross Profit TTM

0 100K 200K 300K Q1 '11: 16K Q2 '11: 35.2K Q3 '11: 43.7K Q4 '11: 57.2K Q1 '12: 146.8K Q2 '12: 203.9K Q1 '13: 216.5K Q2 '13: 187.9K Q1 '14: 293.1K Q4 '15: 130.8K Q1 '16: 97.6K Q2 '16: 89.7K Q3 '16: 109.7K Q4 '16: 150.2K Q1 '17: 129.2K Q2 '17: 112.5K Q3 '17: 129.7K Q4 '17: 87.1K Q1 '18: 91.4K Q2 '18: 83.5K Q2 '11 Q1 '12 Q2 '13 Q1 '16 Q4 '16 Q3 '17 Q2 '18

Operating Income TTM

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -4.1M Q4 '21: -4.2M Q1 '22: -3.3M Q2 '22: -2.8M Q3 '22: -2.3M Q4 '22: -2.4M Q1 '23: -2.4M Q2 '23: -2.9M Q3 '23: -3.9M Q4 '23: -3.8M Q1 '24: -3.8M Q2 '24: -3.4M Q3 '24: -2.7M Q4 '24: -2.2M Q1 '25: -2M Q2 '25: -1.6M Q3 '25: -1.7M Q4 '25: -1.8M Q1 '26: -3.3M Q2 '26: -3.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-6M -4M -2M 0 2M 4M 6M Q3 '21: -3.9M Q4 '21: -4M Q1 '22: -3.3M Q2 '22: -3M Q3 '22: -2.7M Q4 '22: -2.5M Q1 '23: -2.3M Q2 '23: -3.2M Q3 '23: -4.1M Q4 '23: -4.5M Q1 '24: -4.2M Q2 '24: -3.5M Q3 '24: -2.8M Q4 '24: -2.4M Q1 '25: -3.2M Q2 '25: -2.5M Q3 '25: -2.4M Q4 '25: -2.1M Q1 '26: -2.8M Q2 '26: -3.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-2.7M -1.8M -900K 0 900K 1.8M 2.7M Q3 '21: -2.4M Q4 '21: -1.7M Q1 '22: -2M Q2 '22: -1.2M Q3 '22: -1.8M Q4 '22: -1.8M Q1 '23: -1.3M Q2 '23: -1.2M Q3 '23: -837.4K Q4 '23: -775.4K Q1 '24: -698.1K Q2 '24: -615K Q3 '24: -346K Q4 '24: -381.3K Q1 '25: -439.1K Q2 '25: -442K Q3 '25: -417.4K Q4 '25: -526.5K Q1 '26: -597.7K Q2 '26: -874.3K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '20: 97M Q1 '21: 100.1M Q2 '21: 103.4M Q3 '21: 109.9M Q1 '22: 110.8M Q2 '22: 110.8M Q3 '22: 116.4M Q1 '23: 123.5M Q2 '23: 128.8M Q3 '23: 136.4M Q1 '24: 163.4M Q2 '24: 176.6M Q3 '24: 126.4M Q1 '25: 88.8M Q2 '25: 88.8M Q3 '25: 89M Q1 '26: 112.3M Q2 '26: 114.4M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.04 -0.03 -0.01 0.00 0.01 0.03 0.04 Q3 '21: -0.04 Q4 '21: -0.04 Q1 '22: -0.03 Q2 '22: -0.03 Q3 '22: -0.03 Q4 '22: -0.03 Q1 '23: -0.03 Q2 '23: -0.03 Q3 '23: -0.04 Q4 '23: -0.03 Q1 '24: -0.02 Q2 '24: -0.01 Q3 '24: 0.00 Q4 '24: -0.01 Q1 '25: -0.03 Q2 '25: -0.03 Q3 '25: -0.03 Q4 '25: -0.02 Q1 '26: -0.02 Q2 '26: -0.03 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.